A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

Rheumatoid Arthritis (RA) Clinical Trial

Official title:

A Phase 1, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02698657
• Other study ID #: 5094-CL-0102
• Secondary ID: 2015-004562-28
• Status: Completed
• Phase: Phase 1
• Start date: February 23, 2016
• Est. completion date: September 7, 2017

Study information

• Verified date: June 2019
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of multiple ascending intravenous doses of ASP5094 in male and female subjects with rheumatoid arthritis (RA) on methotrexate (MTX).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: September 7, 2017
• Est. primary completion date: September 7, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subject has a body mass index (BMI) of = 35 kg/m2, inclusive, and must weigh at least 50 kg at screening.

• Subject has absolute neutrophil count within normal limits at screening. The assessment may be repeated once during screening.

• Subject has RA that was diagnosed according to the 1987 revised criteria of the American College of Rheumatology (ACR) = 6 months prior to screening.

• Subject meets the ACR 1991 revised criteria for Global Functional Status in RA, Class I, II or III at screening.

• Subject MUST be on concomitant MTX:

• for = 3 months prior to day 1, and

• at a stable dose (10 25 mg/week) for = 28 days prior to day 1 and throughout the study.

• Subject's other medications taken for the treatment of RA at the time of screening must meet the noted stability requirements and remain on a stable regimen, as follows:

• Nonsteroidal antiinflammatory drugs (NSAIDs), selective cyclooxygenase-2 (COX- 2) inhibitors, oral corticosteroids (= 10 mg of prednisone, or equivalent, daily) or low dose opioids (= 30 mg of oral morphine, or equivalent, daily) must be stable for = 28 days prior to screening,

• Hydroxychloroquine (Plaquenil®) and sulfasalazine (e.g., Azulfidine®) must have started = 2 months, and be stable for = 28 days, prior to day 1.

• Female subject must be either:

• Of nonchildbearing potential: postmenopausal (defined as at least 1 year without any menses) prior to screening, or documented surgically sterile

• Or, if of childbearing potential, Agree not to try to become pregnant during the study and for 60 days after the final study drug administration; must have a negative urine pregnancy test at screening and day 1, And, if heterosexually active, agree to consistently use 2 forms of highly effective birth control† (at least 1 of which must be a barrier method) starting at screening and throughout the study period and for 60 days after the final study drug administration.

• Female subject must agree not to breastfeed starting at screening and throughout the study period, and for 60 days.

• Female subject must not donate ova starting at screening and throughout the study period, and for 60 days after the final study drug administration.

• Male subject and his female spouse/partner who is of childbearing potential must be using highly effective forms of contraception consisting of 2 forms of birth control† (1 of which must be a barrier method) starting at screening and continue throughout the study period and for 60 days after the final study drug administration.

• Male subject must not donate sperm starting at screening and throughout the study period, and for 60 days after the final study drug administration

• Subject agrees not to participate in another interventional study while participating in the present study, defined as signing the informed consent form until completion of the last study visit.

Exclusion Criteria:

• Subject has an ongoing clinically significant systemic disease such as uncompensated heart failure, uncontrolled diabetes mellitus, severe hepatic failure, severe pulmonary disease or inflammatory bowel disease.

• Subject has a history of any malignancy in the past 5 years, except for adequately-treated, nonmelanoma skin cancer and adequately-treated in-situ cervical cancer.

• Subject has a history of severe allergic or anaphylactic reactions to drugs.

• Subject has a history of consuming more than 14 units of alcoholic beverages per week or has a history of alcoholism or drug/chemical/ substance abuse within past 6 months prior to screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits).

• Subject has an ongoing infection or has had an infection requiring intravenous antibiotics within 1 month prior to day 1.

• Subject has a known history of a positive test for human immunodeficiency virus (HIV) antibody.

• Subject has a past history of serious opportunistic infection.

• Subject has a positive QuantiFERON-TB Gold test within 90 days of, or at screening, and has not completed an adequate course of antimicrobial therapy per Centers for Disease Control or local guidelines.

• Subject's laboratory test results at screening or prior to study drug dosing on day 1:

• Outside the normal limits and considered by the investigator to be clinically significant with regard to the remaining per-protocol laboratory tests, and/or

• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) are > 2 times the upper limit of normal.

• Subject received any live or live-attenuated vaccine within 30 days prior to day 1.

• Subject received any of the following:

• Oral or injectable gold, azathioprine, penicillamine, cyclosporine, tacrolimus or tofacitinib (Xeljanz®) within 30 days prior to day 1.

• Anakinra (Kineret®), etanercept (Enbrel®), adalimumab (Humira®), tocilizumab (Actemra®), infliximab (Remicade®), or golimumab (Simponi®) within 60 days prior to day 1.

• Leflunomide (Arava®) within 60 days prior to day 1, unless the subject has undergone cholestyramine washout at least 30 days prior to day 1.

• Certolizumab (Cimzia®) and abatacept (Orencia®) within 90 days prior to day 1.

• Rituximab (Rituxan®) or any other antiCD20 antibody, and cyclophosphamide within 180 days prior to day 1.

• Treatment with any other conventional disease modifying antirheumatic drugs (DMARDs), or treatment with any other biologics not previously noted within 28 days or 5 half-lives, whichever is longer, prior to day 1.

• Subject has participated in a previous clinical study with treatment with ASP5094 or has participated in another dose cohort of the current trial.

• Subject has previously received an experimental agent within 28 days or 5 half-lives, whichever is longer, prior to day 1.

• Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to day 1.

• Subject had surgery or has a planned elective surgery (including oral surgery) within 1 month prior to screening and 3 months after last study drug administration.

• Subject has a wound that is currently healing.

• Subject has any other condition, which in the opinion of the investigator, precludes the subject's participation in the trial.

• Subject is an employee of the Astellas group or vendors involved in the study.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis (RA)

Intervention

Drug:
• ASP5094
Intravenous (IV)
• Placebo
Intravenous (IV)

Locations

Country	Name	City	State
Poland	Site PL48009	Elblag
Poland	Site PL48011	Krakow
Poland	Site PL48006	Lodz
Poland	Site PL48007	Stalowa Wola
Poland	Site PL48003	Warszawa
Poland	Site PL48008	Wroclaw
United States	Site US10002	Anniston	Alabama
United States	Site US10001	Dallas	Texas
United States	Site US10008	DeBary	Florida
United States	Site US10003	Duncansville	Pennsylvania
United States	Site US10004	Jacksonville	Florida
United States	Site US10010	Memphis	Tennessee
United States	Site US10009	Miami Lakes	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Global Development, Inc.

Countries where clinical trial is conducted

United States,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with Treatment-Emergent Adverse Events	A treatment-emergent adverse event (TEAE) is defined as a newly occurring or worsening adverse event (AE) observed after starting administration of study drug up until the end of study visit, inclusive. This includes abnormal laboratory tests, vital signs or electrocardiogram data that are defined as AEs if the abnormality induces clinical signs or symptoms, requires active intervention, interruption or discontinuation of study drug or is clinically significant in the investigator's opinion. A serious AE (SAE) is defined as an AE with an outcome that results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly, or birth defect or requires inpatient hospitalization or leads to prolongation of hospitalization.	From first dose of study drug up to end of study (up to 141 days)
Primary	Change from Baseline in Total Lymphocyte Counts		Baseline and days 29, 57, 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: CD19		Baseline and days 29 (predose), 57 (predose), 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: CD19/Lymphocytes		Baseline and days 29 (predose), 57 (predose), 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: CD3		Baseline and Days 29 (predose), 57 (predose), 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: CD3/Lymphocytes		Baseline and Days 29 (predose), 57 (predose), 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: CD4		Baseline and Days 29 (predose), 57 (predose), 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: CD4/Lymphocytes		Baseline and Days 29 (predose), 57 (predose), 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: CD8		Baseline and Days 29 (predose), 57 (predose), 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: CD8/Lymphocytes		Baseline and Days 29 (predose), 57 (predose), 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: Granulocytes		Baseline and Days 29 (predose), 57 (predose), 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: Granulocytes/Leukocytes		Baseline and Days 29 (predose), 57 (predose), 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: Natural Killer Cell Subset/Lymphocytes		Baseline and Days 29 (predose), 57 (predose), 85, 113, 141
Primary	Change from Baseline in Peripheral Lymphocyte Subsets: Natural Killer Cells		Baseline and Days 29 (predose), 57 (predose), 85, 113, 141
Primary	Number of Participants with Anti-ASP5094 Antibody Formation		Days 1 (predose), 29 (predose), 57 (predose), 71, 85, 113 and 141
Primary	Area under the concentration-time curve from the time of dosing on day 1 to the end of the 4-week dosing interval for ASP5094 (AUC)		Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose
Primary	Maximum Concentration (Cmax) of ASP5094		Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose
Primary	Time to maximum concentration (tmax) of ASP5094		Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose
Primary	Concentration immediately prior to dosing at multiple dosing (Ctrough) for ASP5094		Predose on days 29, 57, and 85
Primary	Accumulation ratio calculated using the maximum concentration (R3ac[Cmax]) for ASP5094		Day 57 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose
Primary	Accumulation ratio calculated using the area under the concentration-time curve (R3ac[AUC]) for ASP5094		Day 57 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose
Secondary	Terminal elimination half-life (t1/2)		Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose
Secondary	Total clearance after intravenous dosing (CL)		Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose
Secondary	Volume of distribution after intravenous dosing during the terminal elimination phase (VzF)		Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose
Secondary	Percentage of Fluctuation		Day 1 predose, 0.5, 24, 96, 168, 216, 336, 504, 672 hours postdose

External Links

•   Link to results on the Astellas Clinical Study Results website